Loading lessons…
Loading lessons…
Curated lessons across 8 learning paths — from first concepts to trial summaries and practical protocols. Pick your level, follow the curriculum, and build real understanding.
Where are you starting?
Choose a learning path below or search the library. Progress saves in your browser.
Prefer timeline chaos? Peptide X Quiz · Literacy certify
Pick a track — progress rings update as you complete lessons.
41 lessons
11mGHRP-6 is the original growth hormone-releasing peptide, a synthetic hexapeptide from 1984 that works on the ghrelin receptor. It reliably raises growth hormone in people, which is why endocrinologists used it as a diagnostic test. What it has never had is a trial showing it improves body composition, recovery or any clinical outcome.
10mGonadorelin is a lab-made copy of GnRH, the brain hormone that starts the testosterone and fertility chain. Both US human products were discontinued, current US labels are for cattle, and no published trial has tested it for protecting fertility on testosterone therapy.
14mOn October 28, 2026, HHS said it will not take enforcement action against qualifying 503A compounding for six peptides while FDA rulemaking continues. That is not FDA approval and not a bulks-list addition. This explainer maps the policy in plain language.
9mNAD+ is essential to cells. That does not make every NAD+ treatment effective. A practical guide to IV claims, oral precursors and what human studies actually measured.
9mGHK-Cu is a small copper-binding peptide with decades of lab research and a thin human record. Here's what it is, why topical and injectable use are different questions, and where FDA stands in 2026.
9mBefore you trust any peptide source, run the same checklist a pharmacist would: who is accountable, what was tested, by whom, for which batch, and what the paperwork still cannot tell you.
7mPatients ask about BPC-157 after extractions and implants. The dental literature is one rat periodontitis model, one rat oral-injury model, and three uncontrolled human cases. Here is each one.
8mEnamel matrix derivative and rhPDGF-BB are FDA-approved devices with decades of trials. BPC-157 and TB-500 have one rat study each in periodontitis. Here is the whole picture, with sources.
9mMost peptide stigma is not a single hazard. It is three different risks that clinics mash together. Separate them and the conversation with counsel, pharmacy, and medical directors gets shorter.
8mIf your team cannot state the regulatory status of each compound in one clean sentence, the menu is not ready. Here is the three-band model clinics use before counsel finishes the memo.
7mVendor PDFs are not primary sources. Here is the order clinics should read FDA and state board pages so status sheets survive the first counsel review.
10mAdding peptides to a med spa is a licensing, sourcing and documentation problem before it is a marketing one. Here is the operational order: prescriber, pharmacy, regulatory status by compound, consent, and a way to track what patients actually do between visits.
6mAdamax is marketed as a modified Semax. Semax has decades of mostly Russian research. Adamax has essentially none in the published literature. Here's the honest comparison.
7mThe panel backed six peptide nominations but not Emideltide. Here is why evidence and identity questions mattered, and what the result means for people following sleep peptides.
7mEpitalon received a narrow advisory vote for 503A compounding in insomnia. That vote is not FDA approval, immediate access, or validation of longevity claims.
7mA beginner-friendly guide to KPV, its relationship to alpha-MSH, the evidence behind its nominated uses, and the limits of the 2026 PCAC recommendation.
7mMOTS-c now has a favorable advisory recommendation. It still does not have FDA drug approval or an open 503A compounding path.
7mPCAC recommended BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon for 503A compounding. The unresolved fight is what happens while FDA completes rulemaking.
7mThe favorable Semax vote moved its compounding nomination forward, but the narrow result exposed unresolved questions about evidence, characterization, and US clinical use.
7mTB-500 received a favorable advisory recommendation for wound healing. FDA action still has to follow, and the product sold online may not match the substance the committee reviewed.
7mA favorable advisory vote is not permission to prescribe or compound. Here is the practical standard telehealth clinics should use after the 2026 PCAC meeting.
9mSermorelin is the short GHRH analog older clinic pages still treat as the gentle GH option. The literature is real. The nightly microgram charts are practice culture, not a modern phase 3 program.
8mBPC-157 is still a research compound, but the advisory review makes one thing clear: access, sourcing, and evidence quality now matter as much as the mechanism.
10mRetatrutide may dominate the weight-loss discussion, but the market debate is really about quality control, documentation, and whether a plan can survive real life.
8mThe regulatory story matters because it changes what you can trust, what you should track, and why supply chain quality now sits beside mechanism in the BPC-157 debate.
The FDA's peptide panel made its first moves on BPC-157, KPV, and TB-500. The vote matters, but the real story is what it changes next and what still has to happen before compounding pharmacies see any relief.
8mRegulation does not settle the peptide debate by itself. It forces clearer questions about sourcing, safety, evidence, and who is responsible when claims move faster than data.
The July 2026 FDA peptide review is important, but it is not an approval event. Here is how to track the meeting, sourcing changes, and protocol decisions without confusing policy movement with clinical proof.
7mThe biggest peptide trend in 2026 may not be a molecule. It may be oversight, sourcing quality, and the ability to separate evidence from marketing.
8mThe FDA's April 2026 announcement removed 12 peptides from Category 2 restrictions — the biggest regulatory shift in years. BPC-157, TB-500, MOTS-C, GHK-Cu, and Semax are among those affected. Here's what it actually means for your access.
8mSeven FDA warning letters in April 2026 show regulators are paying closer attention to online peptide sellers, especially research-use-only marketing that looks like consumer health claims.
9mAfter years of FDA crackdowns on research peptides, a significant regulatory reversal in 2026 has changed the landscape for BPC-157, TB-500, and MOTS-C. Here's what actually happened and what it means for you.
8mConfused about peptide compounding categories? This guide breaks down 503a compounding pharmacies, 503b outsourcing facilities, and why “research use only” is not a consumer pathway PeptIQ endorses.
9mNo drug containing GHK-Cu is FDA approved. Topical copper peptides are cosmetics, non-injectable GHK-Cu is still under FDA evaluation, and GHK-Cu is not on the October 2026 HHS peptide list.
9mThe FDA's April 15, 2026 reclassification of 12 research peptides marks the most significant regulatory shift in the space since the 2023 compounding crackdown. Here's a breakdown of the affected compounds, the new compliance landscape, and how to think about your protocol going forward.
10mAn FDA advisory panel scheduled for July 2026 could reshape access to 12 peptides — including BPC-157, MOTS-C, and GHK-Cu. Here's what's on the table, what reclassification would mean in practice, and how to prepare for either outcome.
10mEpitalon is a lab-made four-amino-acid peptide based on a pineal gland extract. It lengthens telomeres in cell studies, but human evidence is small and old. It is not FDA approved, and since October 2026 it is one of six peptides in an HHS compounding policy.
11mIGF-1 LR3 is a lab-modified copy of the IGF-1 hormone, built in 1992 as a research reagent. A 2026 review places it in the tier with no peer-reviewed human studies at all. It is not FDA approved, is regulated as a biologic rather than a peptide, and is prohibited in sport.
9mAfter years of regulatory limbo, BPC-157 is at the center of a major policy battle. The RFK Jr.-led HHS push to reclassify it as Category 1 could restore legal compounding access—or the FDA could dig in. Here's where things stand.
9mMOTS-c is a 16-amino-acid peptide encoded in mitochondrial DNA. It has strong mouse data, one recruiting placebo-controlled human trial and no FDA approval. In October 2026 HHS added it to an interim compounding policy.
11mMelanotan 2 is a synthetic hormone analogue from a University of Arizona tanning program. It darkens skin in people, and it also causes erections, nausea and appetite changes. Its relatives became approved drugs. It never did, and the case-report record explains why regulators keep warning about it.
Also available at /blog for legacy links.